Oxford BioMedica PLC (LSE:OXB) — Market Cap & Net Worth
Market Cap & Net Worth: Oxford BioMedica PLC (OXB)
Oxford BioMedica PLC (LSE:OXB) has a market capitalization of $8.71 Million (GBX71.61 Billion) as of May 4, 2026. Listed on the LSE stock exchange, this UK-based company holds position #27215 globally and #369 in its home market, demonstrating a -6.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oxford BioMedica PLC's stock price GBX593.00 by its total outstanding shares 120751662 (120.75 Million). Analyse Oxford BioMedica PLC cash conversion from operations to see how efficiently the company converts income to cash.
Oxford BioMedica PLC Market Cap History: 2015 to 2026
Oxford BioMedica PLC's market capitalization history from 2015 to 2026. Data shows growth from $4.77 Million to $8.71 Million (4.46% CAGR).
Index Memberships
Oxford BioMedica PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$62.11 Billion | 0.01% | #272 of 573 |
Weight: Oxford BioMedica PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oxford BioMedica PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oxford BioMedica PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Oxford BioMedica PLC's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.77 Million | $15.91 Million | -$13.02 Million | 0.30x | N/A |
| 2016 | $2.99 Million | $27.78 Million | -$16.64 Million | 0.11x | N/A |
| 2017 | $6.50 Million | $37.59 Million | -$9.02 Million | 0.17x | N/A |
| 2018 | $10.39 Million | $66.78 Million | $7.54 Million | 0.16x | 1.38x |
| 2019 | $9.48 Million | $64.06 Million | -$16.07 Million | 0.15x | N/A |
| 2020 | $15.13 Million | $87.73 Million | -$6.25 Million | 0.17x | N/A |
| 2021 | $18.07 Million | $142.80 Million | $19.01 Million | 0.13x | 0.95x |
| 2022 | $6.50 Million | $139.99 Million | -$39.16 Million | 0.05x | N/A |
| 2023 | $3.23 Million | $89.54 Million | -$157.49 Million | 0.04x | N/A |
| 2024 | $6.17 Million | $128.80 Million | -$43.19 Million | 0.05x | N/A |
Competitor Companies of OXB by Market Capitalization
Companies near Oxford BioMedica PLC in the global market cap rankings as of May 4, 2026.
Key companies related to Oxford BioMedica PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Oxford BioMedica PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Oxford BioMedica PLC's market cap moved from $4.77 Million to $ 8.71 Million, with a yearly change of 4.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX8.71 Million | -3.89% |
| 2025 | GBX9.06 Million | +46.90% |
| 2024 | GBX6.17 Million | +90.91% |
| 2023 | GBX3.23 Million | -50.28% |
| 2022 | GBX6.50 Million | -64.02% |
| 2021 | GBX18.07 Million | +19.42% |
| 2020 | GBX15.13 Million | +59.69% |
| 2019 | GBX9.48 Million | -8.80% |
| 2018 | GBX10.39 Million | +59.82% |
| 2017 | GBX6.50 Million | +117.44% |
| 2016 | GBX2.99 Million | -37.38% |
| 2015 | GBX4.77 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Oxford BioMedica PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.71 Million USD |
| MoneyControl | $8.71 Million USD |
| MarketWatch | $8.71 Million USD |
| marketcap.company | $8.71 Million USD |
| Reuters | $8.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oxford BioMedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The… Read more